CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Wu, Y. [1 ,2 ]
Chang, J. [3 ]
Zhang, L. [4 ]
Tu, H. [1 ,2 ]
Wu, L. [5 ]
Feng, J. [6 ]
Lu, S. [7 ]
Zhou, C. [8 ]
Wang, J. [9 ,10 ]
Mok, T. [11 ]
Taylor, F. [12 ]
Mossman, B. [12 ]
Penrod, J. [13 ]
Lawrance, R. [14 ]
Blum, S. [13 ]
Wang, P. F. [13 ]
Cheng, Y. [15 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[4] Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China
[5] Hunan Canc Hosp, Changsha, Hunan, Peoples R China
[6] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
[7] Shanghai Jiao Tong Univ Shanghai, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[8] Shanghai Pulm Hosp, Shang, Peoples R China
[9] Chinese Acad Med Sci, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[10] Peking Union Med Coll, Beijing, Peoples R China
[11] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[12] Adelphi Values, Boston, MA USA
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Adelphi Values, Bollington, England
[15] Jilin Canc Hosp, Changchun, Jilin, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 12期
关键词：
Advanced NSCLC; Nivolumab; Docetaxel; Patient-Reported Outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA10
引用
收藏
页码：S1047 / S1048
页数：2
相关论文
共 50 条
  • [31] Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer
    Bordoni, Rodolfo
    Ciardiello, Fortunato
    von Pawel, Joachim
    Cortinovis, Diego
    Karagiannis, Thomas
    Ballinger, Marcus
    Sandier, Alan
    Yu, Wei
    He, Pei
    Matheny, Christina
    Felizzi, Federico
    Rittmeyer, Achim
    CLINICAL LUNG CANCER, 2018, 19 (05) : 441 - +
  • [32] Development of a Patient-Reported Outcome (pro) Assessment of Core Non-Small Cell Lung Cancer (NSCLC) Symptoms
    Debusk, Kendra
    Johnson, Nathan
    Evans, Christopher
    Jubb, Adrian
    Sandler, Alan
    Ramalingam, Suresh S.
    Campbell, Alicyn K.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S660 - S660
  • [33] DEVELOPMENT OF A PATIENT-REPORTED OUTCOME (PRO) ASSESSMENT OF CORE NON-SMALL CELL LUNG CANCER (NSCLC) SYMPTOMS
    DeBusk, K.
    Johnson, N.
    Evans, C.
    Sandler, A.
    Ramalingam, S. S.
    Campbell, A.
    VALUE IN HEALTH, 2015, 18 (07) : A471 - A471
  • [34] REAL-WORLD (RW) PATIENT-REPORTED OUTCOMES (PROS) IN FRONTLINE MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) IN FRANCE, GERMANY, AND THE UK
    Hanlon, J.
    Bailey, H.
    Khela, K.
    Stojadinovic, A.
    Giove, T. J.
    Kalilani, L.
    Last, M.
    Forshaw, C.
    Hall, J. P.
    Hogea, C.
    VALUE IN HEALTH, 2022, 25 (01) : S228 - S229
  • [35] Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
    Kim, H. R.
    Gridelli, C.
    Kapur, D.
    Tufman, A.
    Felip, E.
    Velcheti, V.
    Kim, Y. J.
    Goetze, T. O.
    Lopez, P. Garrido
    Corre, R.
    Penkov, K.
    Anjum, R.
    Di Pace, B.
    Liu, W.
    Borgovan, T.
    Ledger, D.
    Carver, J.
    Waszak, A.
    Dhar, A.
    Novello, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S109 - S110
  • [36] "Realworld" application of nivolumab and the impact of performance status on outcomes of in patients with advanced non-small cell lung cancer (NSCLC)
    Abbas, Nazim
    Roy, Amitesh
    Klevansky, Myron
    Vatandoust, Sina
    Kichenadasse, Ganessan
    Koczwara, Bogda
    Sukumaran, Shawgi
    Karapetis, Chris
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 82 - 82
  • [37] Long-term outcomes with nivolumab in patients with previously treated advanced Non-Small Cell Lung Cancer (NSCLC)
    Thomas, M.
    Kohlhaeufl, M.
    Reck, M.
    Engel-Riedel, W.
    Kortsik, C.
    Bullinger, L.
    Schneider, C. -P.
    Felip, E.
    Brahmer, J.
    Vokes, E.
    Gettinger, S.
    Geese, W.
    Yoon, D.
    Healey, D.
    Li, A.
    Eberhardt, W. E. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 137 - 137
  • [38] Checkmate 384: A Phase 313/4 Dose Frequency Optimization Trial of Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Harris, Ronald
    Reinmuth, Niels
    Mitche, Paul
    Zhu, Jin
    Chang, I-Fen
    Pichons, Eric
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1298 - S1299
  • [39] Nivolumab in Non-Small Cell Lung Cancer (NSCLC): Facing the Reality
    Merimsky, O.
    Shamai, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2425 - S2425
  • [40] Weekly administration of gemcitabine plus docetaxel in advanced non-small cell lung cancer (NSCLC).
    Sun, Y
    Li, J
    Wu, Y
    Li, L
    Gu, L
    Zhang, L
    Wang, J
    Zhang, X
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 698S - 698S
12345